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Gold(III) porphyrin–PEG conjugates [Au(TPP–COO–PEG5000–OCH3)]Cl (1) and [Au(TPP–CONH–PEG5000–
OCH3)]Cl (2) have been synthesized and characterized. Based on the amphiphilic character of the
conjugates, they were found to undergo self-assembly into nanostructures with size 120–200 nm and
this did not require the presence of other surfactants or components for nano-assembly, unlike most
conventional drug nano-formulations. With a readily hydrolyzable ester linkage, chemotherapeutic
[Au(TPP–COOH)]+ exhibited triggered release from the conjugate 1 in acidic buﬀer solution as well as in
vitro and in vivo without the formation of toxic side products. The nanostructures of 1 showed higher
cellular uptake into cancer cells compared to non-tumorigenic cells, owing to their energy-dependent
uptake mechanism. This, together with a generally higher metabolic rate and more acidic nature of
cancer cells which can lead to faster hydrolysis of the ester bond, aﬀorded 1 with excellent selectivity in
killing cancer cells compared with non-tumorigenic cells in vitro. This was corroborated by ﬂuorescence
microscopy imaging and ﬂow cytometric analysis of co-culture model of colon cancer (HCT116) and
normal colon (NCM460) cells. In vivo experiments showed that treatment of nude mice bearing HCT116
xenografts with 1 resulted in signiﬁcant inhibition of tumor growth and, more importantly, minimal
systemic toxicity as revealed by histopathological analysis of tissue sections and blood biochemisty. The
latter is explained by a lower accumulation of 1 in organs of treated mice at its eﬀective dosage, as
compared to that of other gold(III) porphyrin complexes. Co-assembly of 1 and doxorubicin resulted in
encapsulation of doxorubicin by the nanostructures of 1. The nanocomposites demonstrated a strong
synergism on killing cancer cells and could overcome eﬄux pump-mediated drug-resistance in
a doxorubicin-resistant ovarian cancer cell line (A2780adr) which was found in cells incubated with
doxorubicin alone. Also, the nanocomposites accumulated more slowly in non-tumorigenic cells,
resulting in a lower toxicity toward non-tumorigenic cells. These results indicate the potential application
of 1 not only as an anti-cancer agent but also as a nanoscale drug carrier for chemotherapy., Department of Chemistry and Chemical
ng, Pokfulam Road, Hong Kong, China.
Guangzhou 510632, China
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Gold compounds have received growing interest as chemo-
therapeutics in the past few decades.1–7 Unlike cisplatin and
many other platinum-based drugs which exhibit anti-cancer
properties primarily by targeting DNA,3,8,9 gold(I) and/or gold(III)
complexes have demonstrated a variety of actions, including
inhibition of thioredoxin reductase, direct DNA damage, alter-
ation of cell cycles, proteasome inhibition and modulation of
specic kinases.1,3–7,10–20 These multifaceted modes of action are
important for gold complexes to display potent cytotoxicity
against cancer cells, particularly toward cisplatin- and multi-
drug-resistant cell lines.3–7,15 Among these gold compounds,
gold(III) porphyrin complexes [Au(TPP)]Cl (H2TPP ¼ 5,10,15,20-
tetraphenylporphyrin and its derivatives) show excellent
stability under physiological conditions and only weak inter-
actions with serum proteins,6,7,13 in contrast to other goldThis journal is © The Royal Society of Chemistry 2017
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View Article Onlinecomplexes which decompose quite readily in biological media.2
Stability is believed to be crucial for the promising in vivo anti-
cancer activities of gold(III) porphyrin complexes against
diﬀerent types of carcinoma.6,7,14,15 As is commonly encountered
with metallodrugs,3,21 the main hurdles in the development of
clinically used gold(III) porphyrin complexes for chemotherapy
are their poor bioavailability and high toxicity in normal cells
and tissues.6,7
Nano-formulation22–32 can be a potential solution to the
challenges found in the in vivo application of anti-cancer metal
complexes.22–28 Nanostructures of around 100 nm have been
found to accumulate in the tumor vicinity due to the enhanced
permeability and retention (EPR) eﬀect,22–32 which originates
from the leaky tumor vasculatures and impaired lymphatic
system in solid tumors. Therefore, a signicant improvement in
biodistribution of the drug molecules and a concomitant
reduction in toxic side eﬀects can be accomplished by the
nanostructures when compared to traditional therapeu-
tics.22,23,29–32 One of the conventional approaches for nano-
formulation is to encapsulate drug molecules in nanoscale drug
carriers. For example, cisplatin and its platinum(IV) prodrugs
have been encapsulated by biodegradable polymeric micelles,
liposomes and nanogels.22–24,26–28 Nano-formulations from the
conjugation of platinum complexes onto preformed nano-
structures, such as gold nanoparticles25 and magnetic iron
oxide nanoparticles,28 have also been described. Both method-
ologies have been demonstrated to develop nanostructures with
superior in vitro and/or in vivo anti-cancer eﬃcacy. However, in
view of the skin toxicity that arose from the nanocarrier of Doxil
(liposomal formulation of doxorubicin),33 the toxicity of the
components utilized for nano-formulation, including those
which have been approved by the US Food and Drug Adminis-
tration (FDA) for drug formulation, has received growing
concern.29,31,34 As a result, the development of nanostructures of
metallodrugs with minimal content of the components for
nano-assembly would be an attractive strategy for
chemotherapy.
Metal complexes with sterically unhindered structures can
undergo self-assembly into nano- or microstructures without
the aid of nanocarriers or preformed nanostructures.18,35–46 This
property can be explained by the amphiphilic character of the
metal complexes that gives rise to strong non-covalent interac-
tions for the formation of sophisticated nano- or microstruc-
tures.18,35–46 As a number of cytotoxic metal complexes contain
hydrophobic p-conjugated ligands,6,7,11–21,36,43 it is anticipated
that an introduction of hydrophilic components onto these
metal complexes could render them with amphiphilic proper-
ties, and hence will increase their solubility in aqueous solu-
tions and facilitate the formation of nanostructures for in vivo
accumulation in tumors by the EPR eﬀect. Poly(ethylene glycol)
(PEG), which is a hydrophilic polymer approved by the FDA for
drug formulation,47 is an excellent candidate for the develop-
ment of amphiphilic cytotoxic metal complexes. This is not only
because of its hydrophilic character leading to PEGylated metal
complexes having a good aqueous solubility, but also due to its
known antifouling properties, i.e. to provide steric bulk which
minimizes the interactions of the metal complexes withThis journal is © The Royal Society of Chemistry 2017proteins or other biomolecules in blood serum in order to
prevent rapid clearance of the complexes, which is commonly
found in drug molecules without PEG.47 Although PEG–drug
conjugation is a common methodology in drug administration
for improving eﬃcacy, the formation of nanostructures from
PEG–drug conjugates without the aid of nanocarriers or other
components for nano-assembly has rarely been reported.48 In
view of the strong tendency of amphiphilic metal complexes to
form highly-ordered structures, we were prompted to design
and synthesize gold(III) porphyrin–PEG conjugates. Through
judicious choice of porphyrin ligands and linkers for PEG
conjugation, the gold(III) porphyrin–PEG conjugates could form
interesting nanostructures in aqueous media, and the anti-
cancer gold(III) porphyrin moiety can be released from the
conjugates in cancer cells for eﬀective killing of the cancer cells
without the formation of toxic side products. Moreover, the
nanostructures of gold(III) porphyrin–PEG conjugates could be
further utilized as nanoscale drug carriers for other chemo-
therapeutics to achieve a strong synergistic eﬀect on killing
cancer cells by the co-delivery, as well as minimizing toxic side
eﬀects and overcoming drug resistance found in the adminis-
tration of the chemotherapeutic alone. Herein is described the
self-assembly and anti-cancer properties of multifunctional
gold(III) porphyrin–PEG conjugates.
Results and discussion
Design, synthesis and characterization
The chemical structures of complexes 1–4 and Au1a are depic-
ted in Scheme 1. The gold(III) porphyrin–PEG conjugates are
decorated with multiple functionalities for their anti-cancer
properties. The PEG pendant can render gold(III) porphyrin
complexes with good aqueous solubility while lessening the
reactivity of the complex with biomolecules. Importantly, PEG
also provides complexes with amphiphilic character so that the
gold(III) porphyrin–PEG conjugates can undergo self-assembly
into nanostructures in aqueous media. These properties are
important for improving the in vivo eﬃcacy of gold(III)
porphyrin complexes for anti-cancer treatment with reduced
toxic side eﬀects. To avoid signicantly lowering the cytotoxicity
of the gold(III) porphyrin complexes by the PEG pendant as
observed in other PEG–drug conjugates,47 the ester linkage,
which can be hydrolyzed readily by intracellular esterases
and/or acidic conditions in the tumor vicinity,34,49was employed
to conjugate the PEG and gold(III) porphyrin moiety (complex 1).
The amide counterpart, 2, was also synthesized and examined
to understand the contribution of the cleavable ester linkage on
the anti-cancer properties of gold(III) porphyrin–PEG conju-
gates. It is noteworthy that hydrolysis of the conjugates would
only release the anti-cancer gold(III) porphyrin moiety and the
hydrolyzed product of FDA approved PEG. Therefore, no addi-
tional toxicity would result from the conjugates compared to the
gold(III) porphyrin complex alone.
Gold(III) porphyrin–PEG conjugates 1 and 2 were synthesized
by DCC/HOBt coupling reactions of 4 with H3CO–PEG5000–OH
and H3CO–PEG5000–NH2$HCl, respectively. The crude products in
dichloromethane were precipitated three times in diethyl ether,Chem. Sci., 2017, 8, 1942–1953 | 1943
Scheme 1 (a) Chemical structures of 1–4 and Au1a. (b) Multi-functional properties of 1. (c) Schematic cartoon showing the preparations of
nanostructures of 1 and nanocomposites of 1 and DOX by the self-assembly of 1.
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View Article Onlineand further puried by column chromatography on neutral
alumina using dichloromethane–methanol (50 : 1, v/v) as the
eluent. The complexes were characterized using 1H NMR spec-
troscopy (Fig. S1 in ESI†) and matrix-assisted laser desorption/
ionization time-of-ight mass spectrometry (MALDI-TOF-MS;
Fig. 1a and b and S2†). The polydispersity index (PDI) of 1 and 2
determined from MALDI-TOF-MS were both found to be 1.01,
indicating the high purity of the conjugates. The parent gold(III)
complexes of the conjugates, 3 and 4,50 and Au1a51 wereFig. 1 MALDI-TOF-MS of (a) 1 and (b) 2, using a-cyano-4-hydroxycinna
nanostructures of 1 and (d) nanocomposites of 1 and DOX (NC1) in PBS. (e
in PBS. Energy-dispersive X-ray (EDX) spectra of (f) nanostructures of 1 a
1944 | Chem. Sci., 2017, 8, 1942–1953synthesized according to reported methods, and were well char-
acterized by NMR andMS. Details of the synthesis are included in
the ESI.†
Self-assembly in aqueous media
Conjugates 1 and 2 were found to self-assemble into core–shell
micelles with diameters of ca. 120 and 200 nm, respectively, by
adding their respective acetonitrile solutions into phosphate
buﬀered saline (PBS) followed by evaporation of the volatilemic acid with sodium triﬂuoroacetate as the matrix. TEM images of (c)
) DLS proﬁles of nanostructures of 1 and nanocomposite of 1 and DOX
nd (g) NC1, respectively.
This journal is © The Royal Society of Chemistry 2017
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View Article Onlinesolvent, as revealed by transmission electron microscopy
images (TEM; Fig. 1c and S3a†). Intensity-averaged signals from
dynamic light scattering (DLS) experiments of 1 and 2 were
found to be 120.8  7.2 nm and 177.1  81.2 nm respectively
(Fig. 1e and S3b†), while the zeta potentials of the nano-
structures of 1 and 2 were 0.1  1.6 mV and 0.7  4.2 mV
(Fig. S3c and S4†). The good agreement of the intensity-aver-
aged signals from the DLS experiments with the diameters of
the nanostructures observed in TEM images suggested the DLS
signals corresponding to the hydrodynamic diameters of the
nanostructures of 1 and 2. On the other hand, the almost
neutral zeta potentials of the nanostructures of 1 and 2 vali-
dated the presence of PEG pendant in the shell of the nano-
structures. The identity of gold species in the core of the
nanostructures was supported by the good contrast of the core
in the TEM images (Fig. 1c and S3a†) and energy-dispersive
X-ray (EDX) spectra (Fig. 1f).In vitro cytotoxicity
The in vitro cytotoxicity of 1–3 and Au1a to human cancer cell
lines (HeLa, NCI-H460, HCT116, A2780) and the cisplatin- and
doxorubicin-resistant cancer cell lines (A2780cis and A2780adr),
as well as normal human colon mucosal epithelial cell line
(NCM460), non-tumorigenic immortalized liver cells (MIHA)
and normal lung broblast cells (CCD-19Lu), was evaluated
using a 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyltetrazolium
bromide (MTT) assay (Table 1; Fig. S5a†). The ester-linked
conjugate (1), complex 3 and Au1a all demonstrated superior in
vitro cytotoxicity toward cancer cells, as compared to that of
cisplatin (1 is 5.1–76.9 times more cytotoxic than cisplatin). It is
worth noting that 1 retained most of its activity in killing drug-
resistant cancer cells (A2780cis and A2780adr), while Au1a,DOX
and cisplatin were found to show signicantly lower cytotoxicity
against A2780adr, as compared to the non-resistant A2780 cells
(Table S1†). For non-tumorigenic cells, 3 and Au1a showed IC50
in submicromolar range, which is consistent with the reported
high toxicity of gold(III) porphyrin complexes toward normal
cells.6,7 Interestingly, the nanostructures of 1 were found to be
relatively less toxic in non-tumorigenic MIHA, CCD-19Lu and
NCM460 cells (Table 1), as revealed by the large ratio of IC50 in
non-tumorigenic cells to that in cancer cells (Tables S2–S4†).
The low toxicity of 1 was also found in experiments withTable 1 In vitro cytotoxicity of 1–3, Au1a, DOX, nanocomposite of 1 an
Compound
IC50
a/mM
HeLa NCI-H460 HCT116 A2780 A2
1 1.91  0.48 0.85  0.07 0.39  0.03 0.51  0.09 0
2 46.48  4.40 24.66  4.62 8.24  0.22 13.42  0.18 47
3 0.82  0.12 0.11  0.01 0.09  0.01 0.23  0.02 0
Au1a 0.66  0.04 0.23  0.01 0.09  0.02 0.12  0.02 0
NC1 0.70  0.15 0.41  0.03 0.09  0.01 0.20  0.02 0
DOX 0.57  0.06 0.04  0.01 0.14  0.02 0.05  0.01 0
Cisplatin 19.83  1.42 65.42  5.06 15.70  2.2 2.59  0.30 8
a In vitro cytotoxicity was determined by MTT assay upon incubation of th
This journal is © The Royal Society of Chemistry 2017non-tumorigenic liver L02 and gliocyte CHEM-5 cells
(Table S5†). On the other hand, the conjugate with the amide
linkage (2) was less cytotoxic to both cancer and non-tumorigenic
cells in vitro. To understand the origin of the diﬀerence in cyto-
toxicity of 1–3 and Au1a, the release proles of the conjugates in
aqueous buﬀer solutions and in cells, as well as the cellular
uptake of the complexes, were investigated.Controlled release properties
The rate of the release of the gold(III) porphyrin moiety from the
conjugates in aqueous buﬀer solutions at diﬀerent pH values
was determined according to the reported methodology.24,26,27
Nanostructures of 1 and 2 were dissolved in PBS or sodium
acetate buﬀer (pH 4.0) and then dialyzed against a large volume
of PBS or sodium acetate buﬀer solution in the dark at 37 C
using a 1000 Da cut-oﬀ dialysis membrane (details are included
in the ESI†). The quantity of the hydrolyzed gold(III) porphyrin
moiety at diﬀerent time points was determined by inductively
coupled plasma mass spectrometry (ICP-MS; Fig. 2a). In PBS,
31% and 60% of 1 were hydrolyzed at 6 and 24 h, respectively,
while only 2% and 3% of hydrolyzed product of 2 were found at
5 and 24 h, and more than 89% of 2 remained unhydrolyzed at
96 h. On the other hand, the release of the gold(III) porphyrin
moiety from 1 was found to be faster in more acidic sodium
acetate buﬀer solution (pH 4), with 60% and 96% of the
hydrolyzed product found at 6 and 24 h, respectively (Fig. 2a).
Faster release was also found upon incubation of 2 in pH 4
buﬀer solution compared to that in PBS, but the amount was
still much smaller than that found in the study of 1. As the only
diﬀerence between 1 and 2 is the chemical structure of the
linkage for PEG conjugation, the faster release of the gold(III)
porphyrin moiety from 1 in PBS than that from 2 should be
attributed to the higher tendency of the ester bond in 1 to
undergo hydrolytic cleavage than the amide bond in 2.52 The
faster release from 1 in more acidic buﬀer solution may be
ascribed to acid-catalyzed hydrolysis of the ester bond in 1,49
resulting in almost complete cleavage of the PEG pendant aer
24 h. 1H NMR experiments further supported the hydrolysis of
ester linkage of 1 in acidic solution (pH 4), as indicated by the
disappearance of peaks from protons of –COOCH2CH2– at d ¼
3.98 and 4.67 ppm aer 24 h incubation (Fig. S6†). On the other
hand, no observable change in the NMR spectra of 2 was foundd DOX (NC1), and cisplatin
780cis A2780adr MIHA NCM460 CCD-19Lu
.64  0.03 1.51  0.40 14.49  2.55 16.42  2.45 15.22  1.93
.25  8.62 >120 114.62  17.11 70.96  6.42 >100
.19  0.03 0.65  0.06 0.74  0.09 0.13  0.01 0.73  0.04
.18  0.01 1.13  0.15 0.40  0.07 0.07  0.01 0.23  0.04
.47  0.07 0.53  0.11 3.24  0.37 4.59  1.26 —b
.05  0.01 0.68  0.05 0.10  0.01 1.01  0.12 —b
.36  0.05 12.73  1.83 17.56  1.31 12.32  0.87 49.14  5.43
e live cells with the compounds for 72 h. b Not determined.
Chem. Sci., 2017, 8, 1942–1953 | 1945
Fig. 2 (a) Time-dependent release proﬁles of 1 and 2 in PBS and/or pH
4 buﬀer solution as determined by ICP-MS. (b) Total-ion chromato-
grams of UPLC-QTOF-MS of cell lysates of untreated HCT116 cells
and HCT116 cells treated with 1 and 3 (2 mM), respectively, for 24 h.
Selected-ion chromatograms at m/z ¼ (c) 853 and (d) 867, corre-
sponding to the m/z of [Au(TPP–COOH)]+ and [Au(TPP–COOCH3)]
+,
respectively. (e) MS recorded at t ¼ 6.44 min of the UPLC-QTOF-MS
chromatogram of cell lysates of HCT116 cells treated with 1 (2 mM) for
24 h. Inset: simulated isotopic pattern of [Au(TPP–COOH)]+.
Fig. 3 (a) Uptake of 1, 3 or Au1a (all at 2 mM), in terms of the gold
content determined by ICP-MS, into HCT116 and NCM460 cells,
respectively, after incubation at 37 C for the indicated time intervals.
(b) Uptake of (black) 1, (red) 3, (blue) Au1a or (dark cyan) nano-
composites of 1 and DOX, NC1, ([1] ¼ 2 mM) into (solid line) A2780 and
(dashed line) A2780adr cells, respectively, after incubation at 37 C for
the indicated time intervals. (c) Bar chart showing the ratio of uptake of
the complexes (2 mM) into cancer and non-tumorigenic cells after
incubation for 2 h at 37 C. (d) Uptake of 1 into HCT116 and NCM460
cells after incubation for 2 h in (black) cell culturemediumwith 10 vol%
fetal bovine serum at 37 C, (red) cell culturemediumwith 10 vol% fetal
bovine serum and 0.45 M sucrose at 37 C, (blue) aqueous buﬀer
solution (140 mM NaCl, 20 mM HEPES, 1 mM CaCl2, 1 mM MgCl2 and
1 g L1 D-glucose, pH 7.4) at 37 C and (green) cell culturemediumwith
10 vol% fetal bovine serum at 4 C. All the data are shown as mean 
SEM from three independent experiments. ** denotes p < 0.01 vs.
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View Article Onlineaer incubation in pH 4 or 7.4 solution for 24 h (Fig. S6†),
suggesting the high stability of the amide linkage.
Hydrolysis of the gold(III) complexes in live cells was exam-
ined by ultra-performance liquid chromatography coupled
quadrupole-time-of-ight mass spectrometry (UPLC-QTOF-MS).
Colon cancer cells (HCT116) were treated with 1, 2 and 3 (2 mM)
for 24 h, harvested and lysed in an acetonitrile–water solution
mixture (3 : 1, v/v) prior to UPLC-QTOF-MS analysis. The total-
ion chromatogram of cell lysates of HCT116 treated with 1
showed a peak with retention time of 6.44 min (Fig. 2b) andm/z
¼ 853 (Fig. 2c). The mass spectrum of this peak showed a very
similar isotopic pattern as that of [Au(TPP–COOH)]+ (Fig. 2e). It
is noteworthy that this peak was not found in the total-ion
chromatogram of 1 in acetonitrile solution, while 4 in acetoni-
trile solution showed a peak with almost the same retention
time (6.39 min) in its total-ion chromatogram (Fig. S7†).
Therefore, the peak is attributable to the major metabolite of 1
formed in HCT116 cells. As the peak showed almost the same
retention time as the peak of 4 in acetonitrile solution (Fig. S7†)
and its mass spectrum revealed a very similar isotopic pattern as
that of [Au(TPP–COOH)]+ (Fig. 2e), it should originate from the
chemical species [Au(TPP–COOH)]+, suggesting the hydrolysis of1946 | Chem. Sci., 2017, 8, 1942–1953the ester bond of 1 in HCT116 cells to form [Au(TPP–COOH)]+.
Similarly, hydrolysis of the ester bond was also observed in the
study of 3, which showed the emergence of a peak with a retention
time of 6.42 min in the total-ion chromatogram (Fig. 2c), corre-
sponding to [Au(TPP–COOH)]+ as supported by its mass spectrum
(Fig. S8†). For 2 which has an amide linkage, no release of
[Au(TPP–COOH)]+ can be found from the treated HCT116 cells
(24 h) by UPLC-QTOF-MS analysis (Fig. S9†). This should be
attributable to the higher stability of the amide bond versus the
ester bond in vitro.Cellular uptake experiments
The uptake of 1 and 3, and Au1a by cancer cells and non-
tumorigenic cells was examined in terms of the gold content in
the cell lysates using ICP-MS. In contrast to the gold(III)
complexes without PEG conjugation, i.e. 3 and Au1a, the
gold(III) porphyrin–PEG conjugate 1 was found to show faster
cellular uptake into a variety of cancer cells, such as colorectal
carcinoma (HCT116), human ovarian carcinoma (A2780), and
its drug-resistant variant (A2780adr; Fig. 3a–c). Interestingly,
the uptake of 1 into non-tumorigenic colon and liver cells
(NCM460 and MIHA respectively) was found to be lower than
that of 3 and Au1a (Fig. 3a and S10†), resulting in signicantly
higher uptake into cancer cells compared to that into
non-tumorigenic cells (Fig. 3c). On the other hand, theexperiment with cell culture medium.
This journal is © The Royal Society of Chemistry 2017
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View Article Onlineuptake of 1 into cancer cells was inhibited by lowered tempera-
ture, depletion of K+ concentration and hypertonic sucrose
concentration, unlike the uptake of 3 which was not signicantly
aﬀected by these parameters (Fig. 3d, S11 and S12†). This
suggests that the nanostructures of 1 likely entered live cells by
energy-dependent clathrin-mediated endocytosis, which is in
accordance with reported mechanisms of cellular uptake of
nanostructures.30,32 Due to the generally higher metabolic rate of
cancer cells than normal cells, 1 showed faster accumulation in
cancer cells compared with non-tumorigenic cells (Fig. 3a–c). It is
worth noting that 1 exhibited an increasing concentration in
both A2780 and A2780adr cells with time, while 3 and Au1a
revealed decreases in the amount in A2780adr cells aer incu-
bation for 0.75 and 0.5 h, respectively (Fig. 3b). The decrease of 3
and Au1a in A2780adr cells were likely due to the P-glycoprotein-
mediated drug-resistance of A2780adr cells,53 while the accu-
mulation of 1 in A2780adr cells suggested that the nano-
structures of 1 could overcome the eﬄux pump-mediated drug-
resistance in these cells.Fig. 4 (a) Fluorescence microscopy images of co-cultured HCT116
and NCM460 cells stained with FITC-Annexin V and propidium iodide
after incubation with 1 (2 mM) for 24 h. The NCM460 cells were pre-
treated with blue-emissive CMF2HC dye for diﬀerentiation from
HCT116 cells. The overlaid image was prepared using ImageJ, with
apoptotic cells in green. Analysis by ﬂow cytometry of the co-culture
model of NCM460 cells, which were pre-treated by CMF2HC dye, and
HCT116 cells after incubation with 1 (2 mM) for 24 h and (b) without and
(c) with FITC-Annexin V staining.Higher in vitro cytotoxicity of 1 in cancer cells compared to
non-tumorigenic cells
The controlled release property of 1 (Fig. 2 and S7†) and its
higher cellular uptake by cancer cells (Fig. 3 and S10–S12†)
likely account for the observed higher in vitro cytotoxicity of 1
against cancer cells than that against non-tumorigenic cells
(Tables S2–S4†). Presumably owing to the generally higher
metabolic rate of cancer cells, the nanostructures of 1 accu-
mulated more eﬃciently in cancer cells than in non-tumorigenic
cells. In addition, the acidic character of cancer cells34 would
favor the hydrolysis of 1, leading to a higher rate of release of the
anti-cancer gold(III) porphyrin moiety within cancer cells. On the
other hand, in the less acidic non-tumorigenic cells, 1 is likely to
be hydrolyzed less readily, and the unhydrolyzed gold(III)
porphyrin–PEG conjugates should possess low in vitro cytotox-
icity, as evidenced by MTT assays of cells treated with 2, which
has an amide linkage with a low tendency for hydrolysis. The
latter is attributed to the steric bulk of PEG prohibiting interac-
tions of the gold(III) porphyrinmoiety with its molecular target(s).
For the gold(III) porphyrin complexes without PEG conjugation,
i.e. 3 and Au1a, they demonstrated high in vitro cytotoxicity to
both cancer and non-tumorigenic cells (Table 1 and S2–S4†). This
may be accounted for by their similar cellular uptake rates into
cancer and non-tumorigenic cells (Fig. 3a–c and S10†), resulting
in the non-selective killing of cancer and non-tumorigenic cells.
To gain more insight into the higher cytotoxicity of 1 to
cancer cells, time-dependent assays on the induction of
apoptosis of HCT116 (colon cancer) and NCM460 (normal
colon) cells, by 1 and Au1a were conducted using CellEvent™
Caspase-3/7 Green ReadyProbes® (Caspase-3/7 Green) Reagent.
The Caspase-3/7 Green Reagent is non-luminescent in live cells,
but shows strong green uorescence upon cellular activation of
Caspase-3/7, which is an early indicator of apoptosis.54 Induc-
tion of apoptosis was apparent in both HCT116 and NCM460
cells treated with Au1a (2 mM), at 12 and 20 h, respectively
(Fig. S13b†), while 1 (2 mM) only induced apoptosis in HCT116This journal is © The Royal Society of Chemistry 2017cells aer incubation for 15 h and no signicant apoptosis of
NCM460 cells was found aer treatment with 1, as revealed by
the small number of cells showing green luminescence and the
cell morphology in the bright-eld microscopy images
(Fig. S13b†). Flow cytometric analysis of HCT116 cells treated
with 1 for 24 and 36 h revealed that 35.83 and 43.83% (Q4 region
of Fig. S14 and S15†; corrected by deduction of the percentage of
apoptotic cells found in the negative control) of total population
of cells were apoptotic, while 1.96 and 10.6% of total population
exhibited late apoptotic events (Q2 region; corrected). In
contrast, 1 was less toxic to NCM460 cells, with 100.9 and
90.14% viability (Q3 region; corrected) found aer incubation
for 24 and 36 h respectively. Au1a (2 mM) induced a large
number of apoptotic events in both HCT116 and NCM460 cells
(Fig. S14 and S15†). Smaller populations of viable NCM460 cells
(61.14 and 56.64% [corrected], aer incubation for 24 and 36 h,
respectively) were found, as compared to those treated with 1 for
the same time intervals.
As 1 was found to show faster cellular uptake into HCT116
cells than Au1a (Fig. 3a and c), the induction of apoptosis by 1
aer a longer incubation time indicated a time lag for 1 to
induce Caspase-3/7 activation in HCT116 cells, when compared
to Au1a (Fig. 4a). This can be explained by the time required for
1 to undergo hydrolytic cleavage of the ester bond before
exhibiting its anti-cancer properties. Nonetheless, both 1 and
Au1a (2 mM) could induce apoptosis in a large population of
HCT116 cells aer 48 h (Fig. S13b†), suggesting the readiness of
hydrolysis of 1 in HCT116 cells and the eﬀective killing of these
colon cancer cells by 1. For normal colon NCM460 cells, Au1a
(2 mM) induced their apoptosis aer incubation for 20 h, which
was slightly longer than that found in HCT116 cells, partly
owing to its slower uptake into NCM460 cells (Fig. 3a and c). The
lack of signicant activation of Caspase-3/7 in NCM460 cells
aer incubation with 1 can be rationalized by the relatively slow
uptake of 1 (Fig. 3a and c), in addition to likely slow hydrolytic
cleavage of the PEG pendant of 1 in NCM460 cells.Chem. Sci., 2017, 8, 1942–1953 | 1947
Fig. 5 Fluorescence microscopy images of co-cultured HCT116 and
NCM460 cells stained with CellEvent™ Caspase-3/7 Green ReadyP-
robes Reagent after incubation with 1 (2 mM) for (a) 24 h and (b) 36 h,
respectively. Flow cytometric analysis of the co-culture model stained
with CellEvent™ Caspase-3/7 Green Ready Detection Reagent (2.5
mM) after incubation with (c–e) 1 (2 mM) and (f–h) Au1a (2 mM) for 24 h.
The NCM460 cells were pre-treated with blue-emissive CMF2HC dye
for diﬀerentiation from HCT116 cells. The overlaid images were
prepared using ImageJ.
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View Article OnlineThe induction of apoptosis of HCT116 and NCM460 cells by
1 was further studied using FITC-Annexin V staining. HCT116
cells incubated with 1 and Au1a (2 mM), respectively, for 24 h
were found to show green uorescence from FITC-Annexin V, as
well as red uorescence from propidium iodide which is an
indicator of late apoptotic or necrotic cells (Fig. S16†).54
NCM460 cells treated with Au1a also exhibited green and red
uorescence from FITC-Annexin V and propidium iodide
respectively (Fig. S16b†), while only a small population of
NCM460 cells revealed green uorescence aer incubation with
1 for the same time interval (Fig. S16a†). The quantity of
apoptotic cells stained by FITC-Annexin V aer treatment with 1
or Au1a was also investigated by ow cytometry. Aer
accounting for the background green uorescence from the
negative controls of HCT116 and NCM460 cells (Fig. S17c†), the
percent of apoptotic HCT116 cells aer incubation with 1 and
Au1a for 24 h were found to be 22.5 and 39.6%, respectively,
while 2.4 and 39.3% of NCM460 cells were found to undergo
apoptosis aer treatment with 1 and Au1a respectively
(Fig. S17a and b†). This suggests that 1 was almost non-toxic to
normal colon NCM460 cells upon incubation for 24 h, but
remained active in inducing apoptotic events in colon cancer
HCT116 cells.
To further verify the ability of 1 to selectively induce
apoptosis of HCT116 cells over NCM460 cells, HCT116 and
NCM460 cells were co-cultured and incubated with 1 for 24 h,
and then stained with FITC-Annexin V and propidium iodide. In
order to diﬀerentiate the two diﬀerent cell lines, NCM460 cells
were pre-treated with blue-emissive CMF2HC dye prior to its
co-culture with HCT116 cells. Flow cytometric analysis revealed
successful diﬀerentiation of the two cell lines based on the
detection of the blue uorescence (58.5 and 41.5%; Fig. 4b). In
a parallel experiment, co-cultured cells treated with 1 for 24 h
and stained with FITC-Annexin V and propidium iodide were
imaged by uorescence microscopy (Fig. 4a). Green and red
uorescence were primarily observed in cells without showing
blue luminescence, i.e. HCT116 cells. By ow cytometry
(Fig. 4c), 20.6 and 1.87% of HCT116 and NCM460 cells,
respectively (corrected based on a negative control experiment;
Fig. S18†), were found to undergo apoptosis upon incubation
with 1 (2 mM) for 24 h. The results of both the uorescence
microscopy and ow cytometry support the high selectivity of 1
on killing colon cancer cells in the co-culture model of cancer
and normal cells.
Staining of the co-culture of HCT116 and NCM460 cells
treated with 1 and Au1a (2 mM), respectively, with the Caspase-3/7
Green Reagent showed similar ndings as those of the experi-
ments with FITC-Annexin V staining. Fluorescence microscopy
images of the co-culture model treated with 1 and stained with
Caspase-3/7 Green Reagent revealed strong green uorescence
from HCT116 cells, while only a small population of cells with
blue luminescence, i.e. NCM460 cells, displayed green uores-
cence (Fig. 5a and b). On the other hand, a larger population of
NCM460 cells in the co-culturemodel showed green uorescence
aer incubation with Au1a (2 mM) for 24 and 36 h (Fig. S19†). By
ow cytometric analysis (Fig. 5c–e), the population percentages
of apoptotic HCT116 and NCM460 cells in the co-culture model1948 | Chem. Sci., 2017, 8, 1942–1953aer treatment with 1 and Au1a for 24 h were found to be 25.3
and 4.1%, and 54.6 and 29.3% (corrected based on a negative
control experiment) respectively. Together the data indicate
a high cytotoxicity of Au1a to both HCT116 and NCM460 cells,
while 1 exerts a selective induction of apoptosis in HCT116 cells
over NCM460 cells in the co-culture.
To ensure that the results were not due to the eﬀect of
CMF2HC dye on the co-culture, another co-culture of the two
cell lines was prepared, with the HCT116 cells pre-treated with
CMF2HC dye and hence they would show blue uorescence
upon excitation at 365 nm (Fig. S20†). This co-culture model
treated with 1 for 24 h had 25.04 and 5.01% (Q2 and Q3 regions
of Fig. S21a†; corrected) of HCT116 and NCM460 cells, respec-
tively, undergoing apoptosis as determined by Caspase-3/7
Green Reagent staining and ow cytometric analysis (Fig. S21†).
This conrms the preferential induction of apoptosis by 1 of
HCT116 cells over NCM460 cells in the co-culture model,
regardless of the eﬀect, if any, of the blue emissive CMF2HC dye.Promising in vivo anti-tumor activities with minimal systemic
toxicity
The anti-tumor experiments using mice were approved by the
animal ethics committees of Jinan University and The Univer-
sity of Hong Kong. Treatment of nude mice bearing HCT116
xenogras with 1 (2 or 4 mg kg1) for 24 days through intrave-
nous injection resulted in a signicant reduction of tumor
weight (35 and 53%, respectively; p < 0.01, n ¼ 8; Fig. 6b) and
tumor volume (41 and 58% respectively; p < 0.01, n ¼ 8; Fig. 6c),
with no mouse death or signicant loss in body weight (Fig. 6d).
Histopathological analysis of the tissues of treated miceThis journal is © The Royal Society of Chemistry 2017
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View Article Onlinerevealed that no signicant anomaly was observed in lung, liver,
kidney, heart and spleen aer treatment with 1 (Fig. 7a). The
low systemic toxicity of 1 was further supported by the blood
biochemistry of nude mice aer treatment with 1 (4 mg kg1;
Fig. 7b–i); plasma levels of several organ damage indicators
including alanine transaminase (ALT), globulin (GLB), blood
urea nitrogen (BUN) and creatine kinase (CK) of the treated
mice were lower than those of the untreated mice bearing
HCT116 xenogras (p < 0.05; Fig. 7b, d, e and g), and fell within
the statistically relevant range of those of mice without the
xenogra. In addition, [Au(TPP–COOH)]+ was found in the
UPLC-QTOF-MS of tumor tissues of mice treated by 1, sup-
porting the propensity for hydrolysis of 1 in vivo (Fig. S22†).
On the other hand, intravenous injection of 3 (4 mg kg1) to
nude mice bearing HCT116 xenogras resulted in a signicant
reduction of tumor weight and tumor volume (49 and 56%
respectively; p < 0.01, n ¼ 8; Fig. 6b and c). Yet, higher
concentration of 3 was required to achieve similar inhibition of
tumor growth as found in the treatment with 1 (4.43 mmol kg1
vs. 0.68 mmol kg1), suggesting the more potent anti-tumor
eﬀect of 1. Immunohistochemical analyses of tumor sections
further supported the superior anti-tumor activities of 1 over
that of 3 (Fig. 6a). Eﬀective elimination of nuclear atypia
and mitosis were observed aer treatment of the mice with 1
(4 mg kg1), but not for the treatment with 3 (4 mg kg1). This,
together with the more signicant inhibition of the expression
of Ki67 and VEGFR2, enhanced expression of p53 and elevated
DNA fragmentation (from TUNEL staining) by 1, demonstratesFig. 6 Tumor growth inhibition in nudemice bearing HCT116 xenografts
sections of nude mice (n ¼ 8) after intravenous injections with solvent c
arrows denote the nuclear atypia and mitosis in tumor sections. (b) The tu
doses of 1 or 3, measured at 24 days post treatment. (c) Changes in tu
treatment with solvent control, diﬀerent doses of 1 or 3. The control grou
(e) Biodistribution of gold compounds in diﬀerent organs of nude mice be
(13 mg kg1; n ¼ 5), Au1a (2 mg kg1; n ¼ 4) and 3 (2 mg kg1, n ¼ 4) at
quantiﬁed by ICP-MS. Solvent control was used as background for calcu
organs.
This journal is © The Royal Society of Chemistry 2017that 1 can eﬀectively decrease cancer cell proliferation and
induce cancer cell apoptosis in vivo. More importantly, in
contrast to the low systemic toxicity of 1, histopathological
analysis showed damage in normal lung, liver and kidney
tissues aer treatment with 3 (4 mg kg1; Fig. 7a). Signicant
pulmonary hemorrhage in the alveoli and a thickening of
alveolar walls were found. Also, apoptotic hepatocytes and
swollen renal epithelial cells were found, leading to subsequent
shrinkage of kidney tubules. The blood biochemistry of mice
treated with 3 indicated signicant damage in the lung, liver
and kidney of the mice (Fig. 7b–i). The lower systemic toxicity of
1 can be explained by the lower accumulation of 1 in the organs
of mice treated at its eﬀective dosage, as compared to that of 3
and Au1a (Fig. S23†). In vivo biodistribution study of HCT116
xenograed nude mice subjected to single-dose intravenous
injections of equal molar amount of gold compounds at 24 h
post-treatment revealed higher accumulation of 1 (determined
by ICP-MS analysis) in tumor compared to mice treated with
Au1a (by 3.3-fold) or 3 (by 2.0-fold) (Fig. 6e). As lower gold
contents were found in liver, spleen, lung, kidney and heart of 1-
treatedmice, 1 showed signicantly higher tumor-to-organ ratio
than Au1a or 3 (Fig. 6e). This can be attributable to the nano-
structures of 1, which may lead to in vivo tumor accumulation
by the EPR eﬀect.55
To further investigate the ability of 1 to treat drug-resistant
tumors that should be of great interest in clinical application, in
vivo antitumor experiments on nude mice bearing cisplatin-
resistant A2780cis xenogras with 1 were conducted. Over 52%after treatment with 1 or 3. (a) Immunohistochemical analysis of tumor
ontrol, diﬀerent doses of 1 or 3 every two days for 24 days. The black
mor weight of nude mice (n ¼ 8) treated with solvent control, diﬀerent
mor volume and (d) body weight, respectively, in mice (n ¼ 8) after
p received an equal volume of PBS only. ** denotes p < 0.01 vs. control.
aring HCT116 xenografts after single-dose intravenous injection with 1
24 h post-treatment. The gold contents in homogenized tissues were
lations. Inset shows the ratios of gold content in tumor to that in other
Chem. Sci., 2017, 8, 1942–1953 | 1949
Fig. 7 Evaluation of systemic toxicity in nude mice bearing HCT116 xenografts after treatment with 1 or 3. (a) H & E staining of lung, liver, kidney,
heart and spleen sections from HCT116 xenografted nude mice (n ¼ 8) at 24 days post-treatment. The black arrows in lung, liver and kidney
sections denote sites of pulmonary hemorrhage, apoptotic cells and swollen epithelial cells, respectively. Blood biochemistry analysis of (b) ALT,
(c) AST, (d) GLB, (e) BUN, (f) CREA, (g) UA, (h) LDH and (i) CK in the mice (n ¼ 8) at 24 days post-treatment. Bars with diﬀerent characters were
statistically signiﬁcant at p < 0.05 level.
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View Article Onlinereduction (p < 0.05) of tumor volume was found aer treatment
of mice with 1 (4 mg kg1, intravenous injections for every 2–3
days for 13 days; n ¼ 5; Fig. 8a), with no mouse death or
signicant loss in body weight (Fig. 8b). This suggests that 1 can
be useful for the development of anti-cancer agents for treating
drug-resistant tumors.
Encapsulation of doxorubicin for chemotherapeutic co-
delivery
Doxorubicin (DOX), which has been clinically approved for the
treatment of ovarian cancer and multiple myeloma, elicits
severe cardiotoxicity when it is administered alone.29,30 Also,
resistance to doxorubicin, owing to P-glycoprotein eﬄux pump,
has developed in some types of ovarian cancer cells, such as
those of the A2780adr line.53 In view of the interesting
nanostructures formed by 1, its ability to overcome eﬄux
pump-mediated drug resistance of A2780adr cells as suggested
by the cellular uptake experiments (Fig. 3b) and the relatively
low toxicity toward non-tumorigenic cells than that towardFig. 8 Tumor growth inhibition in nude mice bearing cisplatin-resis-
tant A2780cis xenografts. Change in (a) tumor volume and (b) body
weight, respectively, in nudemice treated with 1 (4 mg kg1) or solvent
control over time. * denotes p < 0.05 vs. control. Data are shown as
mean  SD (n ¼ 5).
1950 | Chem. Sci., 2017, 8, 1942–1953cancer cells, we were inspired to encapsulate doxorubicin in
nanostructures of 1 in an eﬀort to formulate a more potent
therapeutic.
Encapsulation of DOX by nanostructures of 1 was carried out
by co-assembly of 1 and DOX through addition of acetonitrile
solution of 1 (2.5 mg) and DOX (0.18 mg) into PBS, followed by
evaporation of the volatile solvent (Scheme 1c). Nanostructures
of ca. 120 nm were observed in the TEM image of nano-
composites of 1 and DOX (NC1; Fig. 1d). Proles of DLS
experiments and zeta potential measurements indicated that
the nanostructures of NC1 have hydrodynamic radii of 122.1 
13.4 nm and zeta potentials of 2.5  1.6 mV respectively,
similar to those of the nanostructures of 1 (Fig. 1e and S4†). The
gold content in NC1 was conrmed by EDX (Fig. 1g). Due to
signicant overlapping of the UV-vis absorption spectra of 1 and
DOX which hindered the quantication of 1 and DOX in the
nanocomposites, the concentration of 1 in NC1 was determined
by ICP-MS experiments. On the other hand, DOX concentration
in NC1 was measured by UPLC coupled with photodiode array
for detection using daunorubicin hydrochloride as an internal
standard (Fig. S24†). From the results of the two experiments,
the mole ratio of 1 to DOX in NC1, as well as the encapsulation
eﬃciency of DOX by 1, were found to be 7 : 1 and 16.5%,
respectively (Table 2).
An increase in the feed ratio of DOX to 1 was found to
increase the loading of DOX into the nanocomposites (Table 2),
as indicated by UPLC analysis. However, a decrease in encap-
sulation eﬃciency was also found with increasing feed ratio of
DOX to 1 (Table 2). For nanocomposites with diﬀerent DOX
loadings, they were found to show similar size and surface
charge to each other, as reected by the DLS and zeta potential
measurements (Table 2).This journal is © The Royal Society of Chemistry 2017
Table 2 Physiochemical properties of nanocomposites of 1 and DOX
Feed ratio ([1] : [DOX]) Found mole ratio of 1a to DOXb Hydrodynamic diameter/nm Zeta potential/mV %c
NC1 1.41 7 : 1 122.1  13.4 2.5  1.6 16.5
NC2 0.56 2.2 : 1 139.6  20.9 0.8  4.2 11.2
NC3 0.30 1.3 : 1 133.5  19.2 1.2  4.2 9.4
a The concentration of 1 in the nanocomposites was determined by ICP-MS. b The concentration of DOX in the nanocomposites was determined by
UPLC coupled with photodiode array detector using daunorubicin hydrochloride (3.6 mM) as the internal standard. c Encapsulation eﬃciency.
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View Article OnlineSynergistic eﬀect on killing cancer cells and lower toxicity
toward non-tumorigenic cells by NC1
NC1 was found to be more potent in killing cancer cells than
either nanostructures of 1 or DOX (Table 1; Fig. S25†). For
example, according to Caspase-3/7 Green Reagent assays, NC1
([1] ¼ 3.5 mM and [DOX] ¼ 0.5 mM) induced apoptosis in
HCT116 cells aer incubation for 18 h, while a 30 h incubation
was required for signicant induction of apoptosis of HCT116
cells by DOX alone (Fig. S26a†). The in vitro cytotoxicity of NC1
was also compared to that of a mixture of nanostructures of 1
and DOX. Such a combination exhibited higher cytotoxicity to
HeLa cells than either individual component, but was relatively
less eﬀective compared to NC1 (Table 3). The observed cyto-
toxicity was further evaluated by combination index (CI),56
which extrapolates the eﬀect of drug combinations. Based on
the calculated CI value at IC50 of the drug combinations by
CompuSyn,56 both NC1 and the mixture of nanostructures of 1
and DOX showed synergism on killing HeLa cells, with the
former treatment being more potent. The synergistic eﬀect can
originate from diﬀerent molecular targets and/or mechanism of
action of DOX from those of gold(III) porphyrin complexes. DNA
is expected to be the primary target of DOX,57 while gold(III)
porphyrin complexes have been found to cause depletion of
mitochondrial membrane potential and induce apoptosis by
both caspase-dependent and caspase-independent mitochon-
drial death pathways.6 These diﬀerent modes of action would
allow a supra-additive eﬀect on killing HeLa cells by co-delivery.
For the observation of stronger synergism in NC1 than the
mixture of 1 and DOX, this can be attributed to theTable 3 In vitro cytotoxicity of drug combinations of 1 and DOX upon i
Cell lines
Compounds/drug
combinations
1
at IC
HeLa 1 1.91
DOX alone —
Co-incubation ([1] : [DOX] ¼ 7 : 1) 0.74
NC1 0.62
A2780adr 1 1.51
DOX alone —
Co-incubation ([1] : [DOX] ¼ 7 : 1) 0.85
NC1 0.53
MIHA 1 14.4
DOX alone —
Co-incubation ([1] : [DOX] ¼ 7 : 1) 0.57
NC1 3.24
a Combination index determined by CompuSyn.
This journal is © The Royal Society of Chemistry 2017synchronized delivery of the two chemotherapeutics to HeLa
cells from NC1.58
It is noteworthy that NC1 was relatively less toxic to
non-tumorigenic cells than cancer cells (Fig. S26b†; Tables 1
and 3; Tables S6 and S7†). This can be rationalized by slower
uptake of nanostructures of 1 into non-tumorigenic cells
(Fig. 3), and hence likely reduced the uptake of DOX in the form
of NC1, as compared to the administration of DOX alone,
resulting in less eﬀective killing of MIHA cells and the apparent
“strong antagonism” (CI ¼ 4.9; Table 3).
Overcoming eﬄux pump-mediated drug resistance of
A2780adr cells by NC1
The uptake of encapsulated DOX in the form of NC1 by
A2780adr cells was 60.2 and 82.7 mg per g of proteins aer
incubation for 14 and 24 h respectively, based on the analysis of
cell lysates by UPLC-QTOF-MS (Fig. S26c†). On the other hand,
only 33.9 and 27.8 mg of DOX per g of proteins were found in
lysates of A2780adr cells aer incubation with free DOX for 14
and 24 h respectively, and these values are 1.8- and 3.0-fold
lower than those found in the incubation with NC1 for the same
time intervals (Fig. S26c†). This indicates that a signicant
increase inDOX content in A2780adr cells can be achieved when
using 1 as a nanocarrier of the chemotherapeutic, thus over-
coming the eﬄux pump drug-resistance of A2780adr cells.53
The in vitro cytotoxicity of NC1 and mixtures of 1 and DOX
against A2780adr cells was also investigated by MTT assay
(Table 3; Fig. S25b†). From the calculated CI values at IC50 of the
drug combinations, co-incubation of A2780adr cells with 1 andncubation with HeLa, A2780adr and MIHA cells, respectively, for 72 h
50/mM
DOX
at IC50/mM
Total dose
at IC50/mM CI
a
— 1.91 —
0.57 0.57 —
0.11 0.85 0.57
0.09 0.71 0.48
— 1.51 —
0.68 0.68 —
0.12 0.97 0.75
0.08 0.61 0.47
9 — 14.49 —
0.10 0.10 —
0.08 0.65 0.86
0.46 3.80 4.87
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View Article OnlineDOX (CI ¼ 0.75) resulted in moderate synergism,56 while NC1
showed synergism with signicant reduction of eﬀective dosage
for killing A2780adr cells (CI ¼ 0.47).56 The much higher
potency of NC1 than that of the mixtures of 1 and DOX should
not simply be attributed to the synchronized delivery of the two
chemotherapeutics, as observed in the experiments with HeLa
cells (Table 3); in view of the overcoming of eﬄux pump-
mediated drug-resistance by the nanostructures (Fig. 3b and
S26c†), the higher accumulation of DOX in A2780adr cells from
the incubation with NC1 (Fig. 8b) should be the main reason for
eﬀective killing of A2780adr cells.
Conclusions
Multi-functional gold(III) porphyrin–PEG conjugates have been
synthesized and characterized. The amphiphilic conjugate 1
has been found to undergo self-assembly into nanostructures in
aqueous media. Hydrolysis of its ester linkage in acidic buﬀer
solution, live cancer cells or tumor tissues resulted in the
release of the anti-cancer gold(III) porphyrin moiety without the
formation of toxic byproducts. This led to a potent in vitro
cytotoxicity to a panel of cancer cell lines. Together with the self-
assembly into nanostructures and hence higher uptake into
cancer cells than non-tumorigenic cells, 1 has demonstrated
good selectivity in killing cancer cells over non-tumorigenic
cells. This was supported by MTT assays, time-dependent
uorescence microscopy imaging and ow cytometry as well as
experiments exploiting a co-culture model of cancer and normal
cells. Treatment of nude mice bearing HCT116 xenogras with
1 was found to inhibit tumor growth in vivo. Histopathological
analysis of tissue sections and biochemical assays of blood
samples from treated mice suggest a low systemic toxicity of 1.
The in vivo antitumor activities and low systemic toxicity can be
attributable to the nanostructures of 1, leading to tumor tar-
geting by EPR eﬀect and hence low accumulation of 1 in organs
of treated mice. More importantly, 1 could also inhibit tumor
growth in nude mice bearing A2780cis xenogras in vivo,
demonstrating its potential application for the treatment of
cisplatin-resistant tumors. The nanostructures of 1 have been
further utilized to encapsulate chemotherapeutic doxorubicin,
resulting in synergism on killing HeLa cells, as indicated by a low
Combination Index, and lower toxicity to non-tumorigenic cells.
Also, the nanocomposites could overcome eﬄux pump-mediated
drug resistance found in A2780adr cells, thus eﬀective killing of
the drug-resistant cancer cells can be accomplished by the
nanocomposites but not doxorubicin alone. All of these features
suggest that the self-assembly of gold(III) porphyrin–PEG conju-
gate not only allowed the complex to exhibit high eﬃcacy in
killing cancer cells, but also to function as a nanocarrier for drug
co-delivery which should be advantageous for anti-cancer treat-
ment. As a number of reported anti-cancer metal complexes are
known to contain hydrophobicp-conjugated ligands, the present
work opens up a new avenue for the functionalization of hydro-
phobic anti-cancer metal complexes into amphiphilic metal
complexes. Such amphiphilic metal complexes can undergo self-
assembly into nanostructures and achieve promising anti-cancer
properties with a signicant reduction of toxic side eﬀects. Also,1952 | Chem. Sci., 2017, 8, 1942–1953the approach described herein provides new insights into the
utilization of the self-assembly properties of anti-cancer metal
complexes for encapsulation of therapeutics, thus minimizing
the need of components for nano-assembly.Acknowledgements
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